Team Category: Board of Directors

Eric has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for up to $3.5 billion. Prior … Continued

Dr. Cain is the Director of Research at Fairmount, a healthcare investment firm. Prior to joining Fairmount, Dr. Cain served in various positions at the healthcare funds Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Previously, Dr. Cain was a writer and editor … Continued

Mr. Kiselak is a Managing Member at Fairmount, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC. Mr. Kiselak serves as chairman of the board of directors of Viridian Therapeutics and is a director for Apogee Therapeutics, Dianthus Therapeutics, Spyre Therapeutics, … Continued

Dr. Klein is Chief Executive Officer of Oruka Therapeutics and a member of their Board of Directors. Before joining Oruka, he was a Partner at Versant Ventures, where he invested in and helped grow early-stage biotechnology companies. He previously was a member of the CRISPR Therapeutics leadership team and helped grow the company into one … Continued

Erin Lavelle is an accomplished biopharma executive with over 25 years of strategic and operational leadership experience in the biopharmaceutical industry. Most recently as the chief operating officer and chief financial officer of ProfoundBio, Ms. Lavelle led the company’s $1.8 billion acquisition by Genmab and the $112 million oversubscribed Series B financing preceding the acquisition, … Continued